background
littl
known
kinet
tcell
subset
lung
transplant
recipi
ltr
associ
occurr
opportunist
infect
oi
object
analyz
kinet
tlymphocyt
subset
ltr
associ
nadir
tcell
count
viral
infect
transplant
studi
design
serial
measur
peripher
blood
tcell
count
obtain
first
year
posttransplant
consecut
ltr
correl
viral
oi
communityacquir
infect
posttransplant
retrospect
analyz
result
ltr
nadir
tcell
count
cellsl
consist
lower
tcell
count
ltr
nadir
tcell
count
cellsl
p
ltr
nadir
tcell
count
cellsl
cumul
incid
viral
infect
detect
peripher
blood
bronchoalveolar
lavag
bal
sampl
higher
ltr
nadir
tcell
count
cellsl
p
p
respect
nadir
tcell
count
cellsl
within
first
three
month
posttransplant
predict
higher
frequenc
viral
infecti
episod
bal
sampl
within
subsequ
six
month
period
p
conclus
stratif
patient
accord
nadir
tcell
count
may
repres
new
simpl
approach
earli
identif
patient
risk
subsequ
viru
infect
imen
manag
transplant
infect
reject
remain
signific
complic
lung
transplant
recipi
ltr
compar
solid
organ
transplant
recipi
ltr
vulner
infect
relat
intens
immunosuppress
treatment
well
exposur
allograft
environment
agent
thu
opportunist
oi
communityacquir
cai
infect
remain
major
caus
morbid
mortal
ltr
addit
role
viral
infect
favor
occurr
chronic
lung
allograft
dysfunct
suggest
therefor
earli
detect
appropri
treatment
infect
mandatori
improv
outcom
patient
microbi
diagnost
techniqu
develop
andor
improv
year
marker
immunolog
recoveri
predict
risk
infect
transplant
still
routin
appli
followup
period
sever
studi
demonstr
low
tcell
count
repres
major
risk
factor
develop
opportunist
complic
malign
poor
longterm
outcom
individu
human
immunodefici
viru
infect
addit
shown
low
nadir
tcell
count
predict
limit
immun
reconstitut
poor
tcell
recoveri
patient
receiv
antiretrovir
therapi
recent
shown
patient
develop
oi
heart
transplant
low
nadir
tcell
count
low
tcell
count
associ
risk
oi
follow
kidney
transplant
similarli
recent
studi
confirm
low
tcell
count
month
posttranspl
predict
subsequ
occurr
oi
kidney
transplant
howev
limit
data
avail
ltr
analyz
kinet
tcell
count
peripher
blood
obtain
ltr
first
year
transplant
evalu
associ
nadir
tcell
count
develop
viral
infect
posttransplant
eightythre
consecut
patient
receiv
lung
transplant
fondazion
ircc
policlinico
san
matteo
pavia
itali
august
januari
least
oneyear
followup
retrospect
analyz
demograph
characterist
donor
recipi
human
cytomegaloviru
hcmv
serostatu
transplant
indic
type
lung
transplant
induct
therapi
immunosuppress
treatment
acut
reject
episod
caus
death
obtain
patient
medic
record
present
tabl
peripher
blood
bronchoalveolar
lavag
bal
sampl
obtain
part
routin
posttranspl
monitor
infecti
complic
induct
therapi
antithymocyt
globulin
atg
use
ltr
ltr
receiv
standard
tripl
immuosuppress
regimen
includ
calcineurin
inhibitor
cyclosporin
tacrolimu
azathioprin
mycophenol
mofetil
steroid
treat
steroid
puls
episod
acut
reject
diagnos
grade
reject
treat
steroid
bolu
patient
receiv
antivir
drug
ganciclovir
valganciclovir
hcmv
prophylaxi
preemptiv
antivir
therapi
initi
hcmv
dna
level
exceed
copiesml
blood
copiesml
bal
oi
group
consid
infect
relat
cellular
humor
immunosuppress
includ
studi
hcmv
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
human
herpesviru
polyomaviru
infect
defin
presenc
viral
dna
blood
bal
sampl
determin
use
quantit
realtim
pcr
absenc
symptom
viral
syndrom
diseas
defin
accord
establish
criteria
includ
quantif
viral
dna
blood
well
bodi
fluid
biopsi
presenc
symptom
cai
group
includ
infect
could
acquir
commun
hospit
nosocomi
infect
independ
patient
immun
statu
includ
studi
parvoviru
rhinoviru
coronaviru
parainfluenza
viru
adenoviru
influenza
b
parvoviru
rhinoviru
coronaviru
quantifi
realtim
pcr
describ
sampl
test
parainfluenza
viru
adenoviru
influenza
b
direct
fluoresc
antibodi
dfa
stain
describ
sampl
posit
dfa
quantifi
realtim
pcr
adenoviru
influenza
b
peripher
whole
blood
stain
fitcconjug
apcalexa
fluor
apcconjug
peconjug
monoclon
antibodi
beckman
coulter
milan
itali
lysi
red
cell
percentag
lymphocyt
determin
use
navio
tm
flow
cytomet
system
beckman
coulter
absolut
tcell
count
cellsl
calcul
take
account
total
wbc
differenti
lymphocyt
count
estim
autom
hematolog
analyz
use
institut
clinic
laboratori
measur
perform
total
serial
sampl
obtain
first
posttranspl
year
median
number
sampl
per
patient
rang
sinc
individu
heart
transplant
recipi
risk
oi
increas
threshold
tcell
count
circa
cellsl
ltr
analyz
studi
stratifi
relat
arbitrari
tcell
count
cellsl
refer
nadir
tcell
count
tcell
count
tcell
count
tcell
ratio
compar
time
use
longitudin
data
analysi
method
populationaverag
gener
estim
equat
model
autocorrel
order
fit
consid
tcell
count
tcell
count
depend
variabl
presenc
infect
gender
age
nadir
tcell
count
cellsl
cellsl
induct
therapi
type
immunosuppress
regimen
acut
reject
episod
independ
variabl
data
analysi
perform
stata
statist
packag
version
stata
corpor
colleg
station
texa
usa
kaplanmei
method
receiv
oper
characterist
roc
analysi
perform
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
test
twosid
p
consid
statist
signific
baselin
mean
standard
deviat
sd
tcell
count
cellsl
thereaft
increas
time
reach
cellsl
month
fig
mean
tcell
count
baselin
cellsl
level
drop
cellsl
month
one
improv
followup
period
reach
cellsl
month
fig
mean
tcell
ratio
baselin
highest
level
observ
month
one
follow
slight
progress
declin
time
reach
month
fig
twentyf
ltr
nadir
tcell
count
cellsl
median
interquartil
rang
iqr
cellsl
reach
median
iqr
month
posttranspl
wherea
remain
ltr
nadir
tcell
count
cellsl
median
iqr
cellsl
reach
median
iqr
month
posttranspl
patient
nadir
tcell
count
cellsl
maintain
significantli
lower
tcell
count
coeffici
confid
interv
ci
p
month
posttranspl
patient
nadir
tcell
count
cellsl
fig
fact
patient
nadir
tcell
count
cellsl
maintain
high
tcell
count
followup
period
mean
sd
cellsl
baselin
vs
cellsl
month
patient
nadir
tcell
count
cellsl
show
limit
increas
time
cellsl
baselin
vs
cellsl
month
fig
addit
patient
nadir
tcell
count
cellsl
significantli
lower
tcell
count
coeffici
ci
p
patient
nadir
tcell
count
cellsl
fig
hcmv
common
oi
detect
blood
patient
follow
ebv
patient
hcmv
also
frequent
detect
oi
bal
sampl
patient
follow
ebv
four
patient
hsv
vzv
polyomaviru
observ
studi
period
among
cai
rhinoviru
common
patient
follow
coronaviru
nine
patient
parainfluenza
three
patient
influenza
three
patient
adenoviru
one
patient
influenza
b
one
patient
parvoviru
detect
blood
one
patient
highest
proport
patient
system
infect
observ
month
fig
highest
proport
patient
infect
bal
observ
month
transplant
fig
summar
tabl
signific
differ
tcell
count
observ
ltr
without
viral
infect
blood
howev
ltr
develop
viral
infect
bal
significantli
lower
tcell
count
compar
without
infect
p
differ
observ
regard
tcell
count
compar
ltr
without
viral
infect
bal
remark
tcell
count
ltr
depend
nadir
tcell
count
p
addit
tcell
count
higher
men
women
without
reach
statist
signific
ltr
receiv
atg
tend
lower
tcell
count
ltr
acut
reject
episod
tend
higher
tcell
count
tcell
count
appear
depend
age
ltr
nadir
tcell
count
cellsl
cumul
incid
infect
blood
ltr
nadir
tcell
count
cellsl
p
fig
cumul
incid
infect
bal
significantli
higher
ltr
nadir
tcell
count
cellsl
ltr
nadir
tcell
count
cellsl
vs
p
fig
roc
analysi
use
studi
associ
nadir
tcell
count
within
first
three
month
posttransplant
frequenc
infecti
episod
within
success
six
month
period
although
signific
differ
number
infecti
episod
detect
blood
observ
ltr
nadir
tcell
count
cellsl
nadir
tcell
count
cellsl
area
roc
curv
ci
fig
number
infecti
episod
detect
bal
sampl
ltr
nadir
tcell
count
cellsl
significantli
higher
ltr
nadir
tcell
count
cellsl
area
roc
curv
ci
fig
present
studi
provid
detail
analysi
tcell
subset
peripher
blood
first
month
lung
transplant
correl
immunolog
data
infecti
complic
patient
nadir
tcell
count
cellsl
significantli
lower
tcell
count
well
significantli
higher
cumul
incid
viral
infect
ltr
nadir
tcell
count
cellsl
furthermor
nadir
tcell
count
cellsl
within
first
three
month
posttransplant
associ
high
frequenc
infecti
episod
bal
within
subsequ
sixmonth
period
studi
tcell
subset
peripher
blood
obtain
ltr
publish
evalu
associ
infect
restrict
hcmv
pulmonari
infect
differ
observ
cell
ltr
without
hcmv
pulmonari
infect
anoth
studi
decreas
percentag
cell
observ
one
year
posttranspl
ltr
compar
normal
rang
decreas
percentag
cell
patient
hcmv
infect
also
observ
anoth
studi
evalu
differ
lymphocyt
subset
peripher
blood
bal
ltr
percentag
tcell
decreas
tcell
increas
bal
compar
blood
howev
associ
tcell
subset
peripher
blood
pulmonari
infect
fulli
address
present
studi
peripher
tcell
subset
analyz
relat
oi
cai
ltr
found
patient
develop
infect
bal
significantli
lower
tcell
count
without
infect
bal
specimen
increasingli
use
diagnosi
infect
lung
transplant
also
investig
cell
subset
even
though
bal
provid
inform
cellular
compon
present
alveolar
space
number
lymphocyt
compris
small
percentag
total
cell
make
bal
analysi
difficult
standard
thu
result
regard
phenotyp
analysi
lymphocyt
may
contradictori
therefor
base
find
measur
tcell
subset
peripher
blood
could
repres
simpl
less
invas
tool
identifi
ltr
risk
develop
infect
studi
hcmv
frequent
infect
detect
lung
transplant
report
studi
cai
caus
sever
lower
respiratori
tract
infect
ltr
result
import
morbid
mortal
agre
ment
studi
rhinoviru
frequent
isol
ltr
cohort
studi
almost
ltr
receiv
atg
welldocu
effect
atg
treatment
tcell
deplet
keep
recent
studi
data
reveal
ltr
receiv
atg
tend
lower
tcell
count
howev
well
tcell
count
depend
nadir
tcell
count
limit
singlecent
studi
deserv
mention
particularli
associ
retrospect
natur
data
nonsystemat
tcell
measur
rel
small
number
observ
although
studi
limit
find
reveal
associ
nadir
tcell
count
incid
infecti
episod
ltr
suggest
particularli
patient
low
tcell
number
monitor
infect
intensifi
improv
earli
detect
treatment
conclus
stratif
patient
accord
nadir
tcell
count
may
repres
simpl
feasibl
approach
identif
patient
risk
infecti
viral
complic
adopt
tailor
monitor
treatment
schedul
sandra
calarota
particip
studi
design
data
analysi
write
paper
antonella
chiesa
collect
data
particip
analysi
annalisa
de
silvestri
perform
statist
analysi
monica
morosini
particip
perform
studi
collect
data
tiberio
oggionni
piero
maron
federica
meloni
particip
clinic
data
collect
write
paper
fausto
baldanti
particip
studi
design
data
analysi
write
paper
author
approv
final
manuscript
work
support
ministero
della
salut
fondazion
ircc
policlinico
san
matteo
ricerca
corrent
grant
none
declar
retrospect
studi
perform
accord
guidelin
institut
review
board
use
biolog
specimen
scientif
purpos
keep
italian
law
dlg
